Díaz Coppe-Gutiérrez A, Velázquez-Fernández D, Herrera-Hernández MF, Pantoja-Millán JP, Sierra-Salazar M

Idioma: Español
Referencias bibliográficas: 41
Paginas: 83-92
Archivo PDF: 410.92 Kb.

RESUMEN

La incidencia de enfermedad hepática por hígado graso no alcohólico (EHGNA) ha duplicado sus cifras en las últimas décadas. La EHGNA se ha convertido en una causa común de cirrosis; la obesidad es su principal causa. La pérdida de peso se considera la piedra angular del tratamiento de la EHGNA. La cirugía bariátrica ha demostrado ser eficaz en el manejo de la obesidad mórbida y está fuertemente asociada con la mejoría clínica y regresión histológica del amplio espectro de enfermedades que engloba el hígado graso no alcohólico, incluyendo su progresión ulterior, la cirrosis. Actualmente no existe un consenso sobre la seguridad de la cirugía bariátrica en pacientes que padecen EHGNA y obesidad mórbida; de igual manera, se carece de evidencia suficiente para recomendar un procedimiento en particular. En este artículo se detallan las ventajas y riesgos de cada uno de ellos. La cirugía bariátrica puede ser una alternativa segura de tratamiento en pacientes con EHGNA secundaria a obesidad, incluso en aquéllos con diagnóstico perioperatorio de cirrosis hepática.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology 2010; 51(2): 679-89.

2. Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of nonalcoholic fatty liver disease and economy. Dig Dis Sci 2015; 60(11): 3194-202.

3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6): 1387-95.

4. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9(6): 524-530.e1; quiz e60.

5. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-10.

6. Bhala N, Jouness R, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; 19(29): 5169-76.

7. Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54(2): 555-61.

8. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1): CD007340.

9. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient —2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 2013; 21 Suppl 1: S1-27.

10. Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis 2016; 20(2): 339-50.

11. Pham T, Dick TB, Charlton MR. Nonalcoholic fatty liver disease and liver transplantation. Clin Liver Dis 2016; 20(2): 403-17.

12. Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes Surg 2012; 22(7): 1044-9.

13. Tai CM, Huang CK, Hwang JC, Chiang H, Chang CY, Lee CT, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg 2012; 22(7): 1016-21.

14. Ponce J, DeMaria EJ, Nguyen NT, Hutter M, Sudan R, Morton JM. American Society for Metabolic and Bariatric Surgery estimation of bariatric surgery procedures in 2015 and surgeon workforce in the United States. Surg Obes Relat Dis 2016; 12(9): 1637-9.

15. Chousleb E, Rodriguez JA, Oleary JP. History of the development of metabolic/bariatric surgery. In: Nguyen N, Blackstone J, Morton M. The ASMBS textbook of bariatric surgery. New York: Springer; 2015. pp. 37-46.

16. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244(5): 741-9.

17. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104(1): 23-31.

18. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137(2): 532-40.

19. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007; 17(4): 486-92.

20. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg 2006; 16 (5): 607-11.

21. Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014; 260(5): 893-8; discussion 898-9.

22. Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, Schauer P. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis 2016; 12(1): 127-31.

23. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc 2017; 31(3): 1142-7.

24. Ruiz-Tovar J, Alsina ME, Alpera MR; OBELCHE Group. Improvement of nonalcoholic fatty liver disease in morbidly obese patients after sleeve gastrectomy: association of ultrasonographic findings with lipid profile and liver enzymes. Acta Chir Belg 2017: 1-7.

25. Algooneh A, Almazeedi S, Al-Sabah S, Ahmed M, Othman F. Non-alcoholic fatty liver disease resolution following sleeve gastrectomy. Surg Endosc 2016; 30(5): 1983-7.

26. Billeter AT, Senft J, Gotthardt D, Knefeli P, Nickel F, Schulte T, et al. Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass? —A controlled matched pair study of 34 patients. Obes Surg 2016; 26(8): 1867-74.

27. Praveen Raj P, Gomes RM, Kumar S, Senthilnathan P, Karthikeyan P, Shankar A, et al. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial. Surg Obes Relat Dis 2015; 11(6): 1315-22.

28. Stroh C, Köckerling F, Volker L, Frank B, Stefanie W, Christian K, et al. Results of more than 11,800 sleeve gastrectomies: data analysis of the German Bariatric Surgery Registry. Ann Surg 2016; 263(5): 949-55.

29. Busetto L, Tregnaghi A, De Marchi F, Segato G, Foletto M, Sergi G, et al. Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res 2002; 10(5): 408-11.

30. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39(6): 1647-54.

31. Loy JJ, Youn HA, Schwack B, Kurian M, Ren Fielding C, Fielding GA. Improvement in nonalcoholic fatty liver disease and metabolic syndrome in adolescents undergoing bariatric surgery. Surg Obes Relat Dis 2015; 11(2): 442-9.

32. Phillips ML, Boase S, Wahlroos S, Dugar M, Kow L, Stahl J, et al. Associates of change in liver fat content in the morbidly obese after laparoscopic gastric banding surgery. Diabetes Obes Metab 2008; 10(8): 661-7.

33. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135(1): 48-58.

34. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg 2005; 15(10): 1418-23.

35. Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010; 28(1): 274-9.

36. Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during elective obesity operations. Arch Surg 1998; 133(1): 84-8.

37. Dallal RM, Mattar SG, Lord JL, Watson AR, Cottam DR, Eid GM, et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg 2004; 14(1): 47-53.

38. Castillo J, Fábrega E, Escalante CF, Sanjuan JC, Herrera L, Hernánz F, et al. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. Obes Surg 2001; 11(5): 640-2.

39. Papadia F, Marinari GM, Camerini G, Adami GF, Murelli F, Carlini F, et al. Short-term liver function after biliopancreatic diversion. Obes Surg 2003; 13(5): 752-5.

40. Baltasar A, Serra C, Pérez N, Bou R, Bengochea M. Clinical hepatic impairment after the duodenal switch. Obes Surg 2004; 14(1): 77-83.

41. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992; 87(6): 775-9.